Databases drug development

R D Focus. This database service [66] provides information on over 7000 drugs in active development. The service monitors the development, efficacy, and status of pharmaceuticals from early clinical testing through to launch. Data are gathered through direct contact with manufacturers and research organizations. It appraises both the scientific and commercial aspects of drug development and is searchable by product, by phase, by mechanism of action, and by country. R D Focus product is commercially available in several formats. 

The NDA Pipeline. The NDA Pipeline s database [94] of more than 7000 drug development projects is available as a web-delivered, searchable information service that is updated each week. A copy of the annual book, an information service from FDC... 

Collects information, maintains a database of botanical applications, and performs periodic analysis on the status of botanical new drug development. 

Finally, the fourth element is a widened scope of application. The fact that LC/MS is now routinely used during every stage of drug development is a powerful benchmark for acceptance. The increased performance of applications that incorporate LC/MS have, in turn, stimulated new performance levels for sample preparation, high speed separations, automated analysis, information databases, and software tools, to name a few. Motivated by unmet industry needs, the drive for new applications has stimulated tremendous growth in pharmaceutical analysis marked by invention and creativity. 

In view of the clinical importance of the corrected Q-T interval (QTc) prolongation in drug development, the DIDB team has created a new set of data summarizing QTc effects of drugs. In addition, 150 publications already in the database were recently reviewed to highlight the articles with QTc measurement and cases of QTc prolongation. Case reports of torsades de pointes/ventricular fibrillation were also individualized for easy access by DIDB users. 

It is also clear that the new drug discovery will put a renewed emphasis on collaboration and that research on neglected and rare diseases will require this for success to connect disparate researchers around the globe and create virtual drug discovery teams. Currendy available computational database tools for drug discovery, and chemistry in particular, are not collaborative and are of limited application for drug development (13). Therefore at CDD we emphasize collaboration as what differentiates us from other companies and technologies currently available. 

The number of published mechanism-based P D models having an impact on clinical drug development is quite low. A good collection of different types of biological models can be found in the previous chapters of this book. Additionally, the Bio-Models database [38] (http //www.ebi.ac.uk/biomodels/) presents a good collection of different kind of models, some of which might also be applicable to situations in drug development. 

The study of cellular protein expression by proteomics has relied on technologies that first appeared in the 1970s and have been continuously improved. In combination with advanced bioinformatics and large databases, proteomics now provide a powerful tool for basic research, clinical diagnostics, and drug development applications. 

---